Massachusetts Institute of Technology Massachusetts Institute of Technology
Department of Chemical Engineering
Myerson Group
Safety & Training
Job Openings
For Members
Contact Us

The Myerson Group

Back to Members List

Marcus O'Mahony, Ph.D.

Postdoctoral Associate

Dept. Chemical Engineering
Massachusetts Institute of Technology Room: E19-536
77 Massachusetts Avenue
Cambridge, MA 02139

Phone: +1 (617) 324-4525 or
+1 (857) 204-7283





  1. Ph.D. Solid State Pharmaceutical Chemistry – Hodnett/Rasmuson Research group, Solid State Pharmaceutical Cluster (SSPC), University of Limerick, Ireland.
  2. B.Sc. Industrial Biochemistry – University of Limerick, Ireland.


Research summary:

My research is focused on the crystallization, solid state properties and continuous manufacture of pharmaceutical compounds. The topic of my PhD was crystal polymorphism. Specifically, the work focused on understanding the mechanism of the solution-mediated polymorphic transformation for the pharmaceutical compound carbamazepine. The findings of the work identified that the surface of the metastable phase was responsible for promoting the nucleation of the stable phase during the transformation and that this event was associated with the dissolution of the metastable phase. During this work, four principal scenarios were also distinguished for solution-mediated transformations based on solution and solid state monitoring with the relative rates of nucleation, growth and dissolution taken into account.

As a postdoctoral researcher I am currently working on the development of an innovative miniaturized, automated, self-contained and continuous end-to-end pharmaceutical drug manufacturing unit as part of the DARPA Pharmacy on Demand project (July 2014-current).

My previous position within the Myerson Group involved working as part of the heterogeneous nucleation group at the MIT-Novartis Centre for Continuous Manufacturing (March 2013 - July 2014). I developed and investigated a process for the preparation of nanocrystalline active pharmaceutical ingredients (API) confined within a nanoporous substrate during this time, and also developed novel composite dried hydrogels laden with crystalline APIs where the size and the loading of API within the composite phase could be controlled.



End-to-end continuous manufacturing, continuous crystallization, solubility, process analytical technology, nanosized pharmaceuticals, emulsion laden hydrogels, polymorphism, nucleation, dissolution, solution-mediated transformations, crystallography, electron microscopy, X-ray powder diffraction.

The Myerson Group, 77 Massachusetts Ave, Rm 66-568, Cambridge, MA 02139 | Tel: 617.452.3790 | updated: February 13, 2015